Home Tags

View the Latest: Food and Drug Administration (FDA)

Filter

List Grid

1 - 10 of 26 Results

  • The FDA’s Retraction of a Positive Test in the Cyclosporiasis Outbreak Raises Questions About Corrections and Trust

    Quick Insights

    The skepticism surrounding the FDA’s retraction of a positive test tying Taylor Farms lettuce to the cyclosporiasis outbreak comes at a time of broader public distrust in the agency. KFF’s April 2026 Health Tracking Poll found that just over a third (36%) of adults are confident in the FDA to act independently without interference from outside interests, including similarly low shares across partisans.

  • Guardrails for AI in Health Care — How High?

    Podcast

    AI is racing into everyday medicine. The rules of the road are still being written. Dr. Michelle Mello of Stanford, professor at both the Law School and the School of Medicine, and co-leader of its Healthcare Ethical Assessment Lab for AI, joins Chip to address the questions that trail every advance this series has covered: who makes the rules, who ensures the technology gets it right — and who answers when it doesn't?

  • Is AI (Still) Biased? 

    Podcast

    In this episode, Dr. Ziad Obermeyer joins Chip to talk about AI bias in patient management, including how far the health care industry has come since his groundbreaking research that revealed alarming biases in a widely used algorithm that underestimated the health needs of Black patients.

  • Bench to Bedside at AI Speed

    Podcast

    How can AI determine who gets matched to new therapies, who is identified for clinical trials, and how patient tracking is scaled across large populations? Chip is joined by Dr. A.J. Blood, a practicing cardiologist at Brigham and Women's Hospital and the co-founder and Chief Executive Officer of AIwithCare, a startup company that delivers AI-enabled solutions for research, clinical operations, and patient care. They discuss the role of AI in identifying patients for clinical trials…

  • Supreme Court Leaves Mifepristone Access Unchanged – For Now

    Quick Insights

    In addition to ongoing litigation, last September the Trump administration FDA, after  requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety.  This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear. 

  • KFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitor

    Feature

    KFF’s latest Health Tracking Poll finds that confidence in the independence of key government health agencies overseeing food and drug safety and public health is low among the public and across partisans. Most of the public also share a distrust of agriculture, food, and pharmaceutical companies to act in the public’s best interest, compared with doctors and health care providers who are much more trusted among the public. The latest edition of the Monitor also…

  • Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

    Issue Brief

    This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the other pending litigation involving mifepristone, and the mounting tension between states seeking to protect abortion and the states banning the provision of abortion.